Personalized therapies are emerging as a promising approach to treat cancer. Because of the diversity of genetic background and medical history, customizing treatments and leveraging specific characteristics of individual patients are the key strategies to ensure the best possible outcome. Cancer immunotherapies are at the forefront of this type of personalized approach. In recent years, we have observed the unprecedented success of immunotherapies that harness the patient’s own immune system to fight cancer. For example, adoptive cell therapies utilize a patient's own immune cells to kill tumor cells. Neoantigen vaccines can activate T cells that are specific to tumor mutations identified from individual patients. These efforts will pave the way for the next chapter of cancer therapy.
Despite the advances of cancer therapies in recent years, many patients still die of cancer each year. Personalized immunotherapies may provide us a promising strategy, because they can respond to the heterogeneity and uniqueness of each cancer using the likewise unique immune system in each patient. Although the effectiveness of this personalized approach has been shown in literature, it is still limited to a minority of patient populations. Additionally, the complexity of customizing a new therapy for each patient entails high costs and technical challenges. With this research topic, we plan to address the challenges and identify the solutions for the problems in developing personalized immunotherapies. We will gather a group of experts to provide their expertise in the topic of personalized cancer immunotherapies.
This Research Topic will provide an overview of the different types of personalized immunotherapies for cancer that are currently available, but it will also welcome new and innovative approaches. The Research Topic will encompass Review and Original Research articles with focus on, but not limited to:
1) neoantigen-targeted approaches
2) adoptive cell therapies (TILs, CAR-T and TCR-T therapy, etc.)
3) personalized vaccines
4) emerging solutions for personalized manufacturing
5) combination therapies
6) emerging tools to optimize personalized treatments (e.g., bioinformatic, immune-signatures, biomarkers)
Important Note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
Personalized therapies are emerging as a promising approach to treat cancer. Because of the diversity of genetic background and medical history, customizing treatments and leveraging specific characteristics of individual patients are the key strategies to ensure the best possible outcome. Cancer immunotherapies are at the forefront of this type of personalized approach. In recent years, we have observed the unprecedented success of immunotherapies that harness the patient’s own immune system to fight cancer. For example, adoptive cell therapies utilize a patient's own immune cells to kill tumor cells. Neoantigen vaccines can activate T cells that are specific to tumor mutations identified from individual patients. These efforts will pave the way for the next chapter of cancer therapy.
Despite the advances of cancer therapies in recent years, many patients still die of cancer each year. Personalized immunotherapies may provide us a promising strategy, because they can respond to the heterogeneity and uniqueness of each cancer using the likewise unique immune system in each patient. Although the effectiveness of this personalized approach has been shown in literature, it is still limited to a minority of patient populations. Additionally, the complexity of customizing a new therapy for each patient entails high costs and technical challenges. With this research topic, we plan to address the challenges and identify the solutions for the problems in developing personalized immunotherapies. We will gather a group of experts to provide their expertise in the topic of personalized cancer immunotherapies.
This Research Topic will provide an overview of the different types of personalized immunotherapies for cancer that are currently available, but it will also welcome new and innovative approaches. The Research Topic will encompass Review and Original Research articles with focus on, but not limited to:
1) neoantigen-targeted approaches
2) adoptive cell therapies (TILs, CAR-T and TCR-T therapy, etc.)
3) personalized vaccines
4) emerging solutions for personalized manufacturing
5) combination therapies
6) emerging tools to optimize personalized treatments (e.g., bioinformatic, immune-signatures, biomarkers)
Important Note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
